Comorbidities in primary cicatricial alopecia: a systematic review and meta-analysis
Issued Date
2025-01-01
Resource Type
eISSN
16643224
Scopus ID
2-s2.0-105016155418
Pubmed ID
40948796
Journal Title
Frontiers in Immunology
Volume
16
Rights Holder(s)
SCOPUS
Bibliographic Citation
Frontiers in Immunology Vol.16 (2025)
Suggested Citation
Yongpisarn T., Tejapira K., Suchonwanit P. Comorbidities in primary cicatricial alopecia: a systematic review and meta-analysis. Frontiers in Immunology Vol.16 (2025). doi:10.3389/fimmu.2025.1516407 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/112214
Title
Comorbidities in primary cicatricial alopecia: a systematic review and meta-analysis
Author(s)
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Background: Primary cicatricial alopecia (PCA) is known to be associated with various comorbidities; however, findings regarding the likelihood of specific comorbidities in PCA patients have been inconsistent. Objective: This study aimed to assess the prevalence and odds of specific comorbidities in patients with PCA compared to controls, and to explore the distribution of comorbidities across various types of PCA. Methods: Electronic searches were conducted using PubMed, Embase, and Scopus from the dates of their inception until July 2024. A total of 116 studies with 33,494 PCA patients that reported data allowing for the calculation of odds ratios (OR) or prevalences of certain comorbidities in PCA patients were included. Results: Systemic lupus erythematosus is more prevalent among patients with lichen planopilaris (LPP) [OR 3.10 (95% confidence interval: 2.24–4.29), prevalence 2%], frontal fibrosing alopecia (FFA) [OR 6.92 (2.73–17.56), prevalence 5%], and central centrifugal cicatricial alopecia (CCCA) [OR 3.13 (1.03–9.49), prevalence 5%]. Hypothyroidism is more prevalent among patients with LPP [OR of 1.73 (1.24–2.42), prevalence 17%] and FFA [OR 1.86 (1.36–2.55), prevalence 19%]. LPP patients are prone to having dermatological diseases such as atopic dermatitis [OR 3.96 (1.14–13.81), prevalence 9%], lichen planus [OR 19.21 (1.47–251.02), prevalence 8%], psoriasis [OR 4.75 (2.04–11.06), prevalence 3%], and rosacea [OR 4.62 (2.96–7.19), prevalence 5%], while FFA patients are prone to having allergic contact dermatitis [OR 3.19 (1.44–7.08), prevalence 41%] and rosacea [OR 2.37 (1.72–3.29), prevalence 16%]. Coronary artery disease is found to be more common in LPP than controls [OR 1.63 (1.43–1.86), prevalence 8%], while dyslipidemia is more common among FFA [OR 1.41 (1.06–1.88), prevalence 20%] and CCCA [OR 4.46 (1.01–19.75), prevalence 54%] than controls, and diabetes mellitus is more prevalent among CCCA than controls [OR 1.67 (1.03–2.69), prevalence 26%]. While skin cancer [OR 2.22 (1.33–3.70), prevalence 2%] and melanoma [OR 4.46 (1.70–11.76), prevalence 1%] were found to be more common in LPP than controls, rheumatoid arthritis [OR 1.65 (1.09–2.51), prevalence 4%] was found to be more common in FFA than controls, and allergic rhinitis [OR 11.77 (1.55–89.24), prevalence 24%] and anxiety [OR 4.69 (1.29–16.98), prevalence 17%] were found to be more common in CCCA than controls. Conclusions: Patients with PCA are at higher risk of developing a wide range of comorbidities. Physicians should remain vigilant and conduct thorough investigations when clinical clues are present. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=564852, identifier CRD42024564852.